EU panel supports broader approval of Pfizer's Prevenar 13

09/25/2011 | Reuters

People age 50 and older should be allowed to receive Prevenar 13, a pneumococcal vaccine by Pfizer, said the European Medicines Agency's Committee for Medicinal Products for Human Use. The vaccine is indicated for younger children in the EU and the U.S., where it is marketed as Prevnar 13. The FDA previously asked for more time to evaluate the wider use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA